Top

Published in:

01-10-2019 | Images that Teach

Non-diagnostic ¹⁸F-FDG PET myocardial viability studies in type-2 diabetic patients

Authors: Roberto C. Valentin, MD, Ayman Farag, MD, Fadi G. Hage, MD, Pradeep Bhambhvani, MD

Published in: Journal of Nuclear Cardiology | Issue 5/2019

Excerpt

¹⁸F-FDG PET is a valuable functional imaging tool and the only FDA-approved technique for assessing viable myocardium in ischemic cardiomyopathy. It is based on the recognition that resting LV dysfunction may be reversible from myocardial hibernation/stunning, and not necessarily due to an irreversible myocardial scar.1 We report a case highlighting the pitfall of ¹⁸F-FDG PET myocardial viability study performed with the standardized protocol of oral glucose loading and intravenous regular insulin injections in a type-2 diabetic patient with non-diagnostic images. …

Dilsizian V, Bacharach SL, Beanlands RS, Bergmann SR, Delbeke D, Dorbala S, et al. ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures. J Nucl Cardiol. 2016;23:1187-226.CrossRefPubMed

Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007;115:3213-23.CrossRef

Vitale GD, deKemp RA, Ruddy TD, Williams K, Beanlands RS. Myocardial glucose utilization and optimization of (18)F-FDG PET imaging in patients with non-insulin-dependent diabetes mellitus, coronary artery disease, and left ventricular dysfunction. J Nucl Med. 2001;42:1730-6.PubMed

Title: Non-diagnostic 18F-FDG PET myocardial viability studies in type-2 diabetic patients
Authors: Roberto C. Valentin, MD
Ayman Farag, MD
Fadi G. Hage, MD
Pradeep Bhambhvani, MD
Publication date: 01-10-2019
Publisher: Springer International Publishing
Published in: Journal of Nuclear Cardiology / Issue 5/2019
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-018-1420-7

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Non-diagnostic ¹⁸F-FDG PET myocardial viability studies in type-2 diabetic patients

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2019

Improved diagnostic accuracy of thallium-201 myocardial perfusion single-photon emission computed tomography with CT attenuation correction

Prolonged dipyridamole administration reduces myocardial perfusion defects in experimental chronic Chagas cardiomyopathy

Non-invasive assessment of endarteritis in Marfan syndrome with aortic dissection after surgical treatment

Utilization of stress testing for low-risk patients with chest discomfort in the emergency department

The role of multimodality imaging in takotsubo cardiomyopathy

Chronic total occlusion without collateral blood flow does not exclude myocardial viability and subsequent recovery after revascularization

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page